Furthermore, the U.S. Food and Drug Administration (FDA)-approved anthelmintic drug niclosamide was identified to inhibit S100A4-induced metastasis formation of colon cancer, by preventing β-catenin/T-cell factor (TCF) complex formation and therefore transcription of S100A4 [216]. Here, S100A4 is linked to malignant colon neoplasm.